Immune related adverse events and response to immunotherapy: focus on corticosteroids

In their article, Baldini et al. evaluated the association between immune-related adverse events (irAEs) and clinical benefit among patients with non-small-cell lung cancer (NSCLC) treated with nivolumab in the Italian NSCLC expanded access program [1]. Accumulating evidence suggest that there is a correlation between irAEs incidence and therapeutic outcomes of immunotherapy. This has been widely demonstrated in several solid tumors, mostly in patients with melanoma [2] and NSCLC [3]. However, most retrospective reports in NSCLC mainly include patients of Asian ethnicity [4], and differences in treatment tolerability and outcomes may be hypothesized.

Source: Lung Cancer - February 17, 2020 Category: Cancer & Oncology Authors: Alice Indini, Erika Rijavec, Francesco Grossi Source Type: research